Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis

Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis

Background: Coronary disorders are recognized as the most common manifestation of fluoropyrimidine-related cardiotoxicity in clinical practice. However, there are limited and conflicting data on the incidence and profiles of fluoropyrimidine-related coronary disorders. In this meta-analysis, we aime...

Full description

Bibliographic Details
Main Authors:	Yajie Lu, Shizhou Deng, Qiongyi Dou, Wei Pan, Qingqing Liu, Hongchen Ji, Xiaowen Wang, Hong-Mei Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Pharmacology
Subjects:	coronary disorder 5-FU capecitabine meta-analysis fluoropyrimidine
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.885699/full

Similar Items

Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis
by: Yajie Lu, et al.
Published: (2023-03-01)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
by: Linda Cucciniello, et al.
Published: (2022-09-01)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
by: Michał Jurczyk, et al.
Published: (2021-09-01)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
by: Anthi Maslarinou, et al.
Published: (2023-05-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
by: Seid Hamzic, et al.
Published: (2020-11-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
by: Georgia Ragia, et al.
Published: (2023-09-01)

Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report
by: Yoshitaka Saito, et al.
Published: (2021-03-01)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
by: Laura Grumetti, et al.
Published: (2022-01-01)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
by: Raffaele Palmirotta, et al.
Published: (2019-03-01)

Elevated Risk of Fluoropyrimidine-Associated Toxicity in European Patients with <i>DPYD</i> Genetic Polymorphism: A Systematic Review and Meta-Analysis
by: Woorim Kim, et al.
Published: (2022-02-01)

Side Effects and Disease-Free Survival with Capecitabine Compared to 5FU for Concurrent Radiochemotherapy of Rectal Cancer: A 5-year Review
by: Peiman Haddad, et al.
Published: (2014-01-01)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
by: Masashi Kanai, et al.
Published: (2023-04-01)

5-FU induced cardiotoxicity: case series and review of the literature
by: Cai Yuan, et al.
Published: (2019-09-01)

Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia
by: Hatouf H. Sukkarieh, et al.
Published: (2023-02-01)

The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease
by: Natalia Fabin, et al.
Published: (2022-02-01)

Acute Aortic Thrombosis Following Capecitabine Chemotherapy in a Patient with Colon Cancer
by: Min Kyung Lee, et al.
Published: (2018-09-01)

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
by: Eiji Hishinuma, et al.
Published: (2020-07-01)

Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
by: Jorge E. B. da Rocha, et al.
Published: (2021-03-01)

Folinic Acid Enhanced Cytotoxicity of Fluoropyrimidines In Human Breast Cancer Cells
by: Mandelbaum-Shavit Frederika
Published: (1993-02-01)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
by: Chi C. Tong, et al.
Published: (2018-07-01)

Enhanced Therapeutic Efficacy of the Nanoscale Fluoropyrimidine Polymer CF10 in a Rat Colorectal Cancer Liver Metastasis Model
by: Charles Chidi Okechukwu, et al.
Published: (2024-03-01)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
by: Elena De Mattia, et al.
Published: (2022-10-01)

Capecitabine/Mitomycin versus 5-Fluorouracil/Mitomycin in Combination with Simultaneous Integrated Boost Intensity-Modulated Radiation Therapy for Anal Cancer
by: Laurent Mineur, et al.
Published: (2023-09-01)

Risk of cardiovascular disease among different fluoropyrimidine-based chemotherapy regimens as adjuvant treatment for resected colorectal cancer
by: Wen-Kuan Huang, et al.
Published: (2022-08-01)

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
by: Pavlina Spiliopoulou, et al.
Published: (2024-04-01)

Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series
by: Neethu Jose, et al.
Published: (2022-05-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
by: Young Saing Kim, et al.
Published: (2017-01-01)

Capecitabine—A “Permanent Mission” in Head and Neck Cancers “War Council”?
by: Camil Ciprian Mireștean, et al.
Published: (2022-09-01)

Immune infiltration and immune gene signature predict the response to fluoropyrimidine-based chemotherapy in colorectal cancer patients
by: Xianwei Mo, et al.
Published: (2020-01-01)

Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea
by: Miho Sakumura, et al.
Published: (2020-10-01)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
by: Elena De Mattia, et al.
Published: (2023-11-01)

Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies
by: Hiroyuki Kozai, et al.
Published: (2024-02-01)

Dysregulated Pyrimidine Biosynthesis Contributes to 5-FU Resistance in SCLC Patient-Derived Organoids but Response to a Novel Polymeric Fluoropyrimidine, CF10
by: William H. Gmeiner, et al.
Published: (2020-03-01)

Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy
by: Uğur Nadir Karakulak, et al.
Published: (2016-02-01)

<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by: Theodore J. Wigle, et al.
Published: (2023-01-01)

A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies
by: Dominic Schaerer, et al.
Published: (2020-10-01)

A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature
by: Valeria Conti, et al.
Published: (2020-09-01)

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy
by: Elena De Mattia, et al.
Published: (2018-10-01)